Symvess biologic vascular conduit featured by Humacyte at vascular surgery conference

Symvess biologic vascular conduit featured by Humacyte at vascular surgery conference
Humacyte unveils Symvess at conference

Humacyte announced that Dr. Blakeslee-Carter presented the company's Symvess biologic vascular conduit at the Texas Society for Vascular and Endovascular Surgery Annual Meeting.

The presentation focused on Symvess as a treatment option for extremity arterial injury, shedding light on the evolving role of biologic conduits in vascular surgery. No additional commercial or regulatory details were provided in the announcement.

Humacyte has recently presented interim Phase 3 V012 results for its ATEV biologic conduit for hemodialysis access in women at Kidney Week, according to a previous company announcement. The company is also scheduled to share further Phase 3 ATEV trial data in women needing hemodialysis access at ASN Kidney Week 2026, as detailed in another planned presentation. These events reflect ongoing clinical efforts around Humacyte’s biologic vascular technologies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.